相关临床试验
31
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2022
进行中（未招募）
1
3.2%
已完成
12
38.7%
Enrolling By Invitation
1
3.2%
尚未招募
7
22.6%
招募中
8
25.8%
Unknown
2
6.5%
暂无批准数据
- Researchers at Osaka Metropolitan University found that the mitochondrial fusion protein OPA1 in hypothalamic MC4R neurons regulates appetite and body weight in a sex-dependent manner. - Mice lacking OPA1 consumed more food, gained more weight with age, and preferentially consumed more dietary fat, with effects especially pronounced in females. - The anti-obesity MC4R agonist setmelanotide suppressed appetite in males but showed significantly weaker appetite-suppressing effects in OPA1-deficient females. - The findings, published in the FASEB Journal, may inform sex-aware obesity treatments and future personalized medicine approaches.
- Researchers at Osaka Metropolitan University developed a novel drug delivery system using lipocalin-type prostaglandin D synthase (L-PGDS) enzyme as a carrier for paclitaxel, improving the anticancer drug's solubility by approximately 3,600-fold compared to phosphate-buffered saline suspension. - The team enhanced the system by attaching CRGDK targeting peptide to create L-PGDS-CRGDK, which binds to neuropilin-1 receptors on cancer cell surfaces for selective delivery to tumor tissues. - In mouse models with MDA-MB-231 breast cancer cells, the PTX/L-PGDS-CRGDK formulation demonstrated superior and sustained antitumor effects that persisted even after treatment cessation, outperforming commercially available paclitaxel formulations. - The breakthrough addresses critical challenges in cancer drug delivery, particularly for poorly water-soluble compounds with large molecular weights up to approximately 850, potentially advancing future cancer treatment strategies.
- Researchers from Osaka Metropolitan University found that lecanemab reduces amyloid-β plaques but does not restore the brain's glymphatic waste clearance system within three months of treatment. - The study used DTI-ALPS imaging to measure glymphatic function and found no significant improvement in the index between pre-treatment and three months post-treatment. - The findings suggest that neuronal damage and clearance system deficits are already well-established by the time symptoms appear, highlighting the need for multi-targeted therapeutic approaches. - Future research will examine factors like age, disease stage, and white matter lesions to better understand treatment outcomes and optimize patient care.
- Japanese researchers at Osaka Metropolitan University successfully developed fat-derived stem cell spheroids combined with β-tricalcium phosphate that significantly improved bone regeneration and strength in rats with osteoporotic spinal fractures. - Korean scientists at KRICT created nanobiohybrid spheroids by integrating mesoporous silica nanoparticles with human adipose-derived stem cells, achieving 36% bone regeneration in mouse skull defects within six weeks. - Both studies demonstrate enhanced osteogenic differentiation and improved cell viability compared to conventional stem cell approaches, offering potential new treatments for bone fractures in aging populations. - The technologies address critical limitations of current 3D stem cell aggregates, including core cell death and non-uniform differentiation, through innovative scaffold and delivery mechanisms.
- Researchers at Osaka Metropolitan University developed GAI-17, a novel stroke treatment that significantly reduces brain cell death and paralysis in animal models by inhibiting GAPDH protein aggregation. - The drug demonstrated effectiveness even when administered six hours after stroke onset, potentially extending treatment windows well beyond current therapeutic standards. - GAI-17 showed no major side effects in preclinical studies and may have broader applications for treating other neurological diseases including Alzheimer's disease. - The compound targets a multifunctional protein linked to various intractable brain disorders, offering potential for a new class of neuroprotective therapies.
- Shionogi and Osaka Metropolitan University have established a comprehensive collaboration agreement focused on infectious disease research, diagnostics development, and public health system strengthening. - The partnership will leverage Osaka Metropolitan University's broad academic expertise through OIRCID and Shionogi's pharmaceutical innovation capabilities to create an 'Osaka Model' for pandemic preparedness. - The collaboration encompasses education, research, public health system enhancement, and policy development, with specific focus on preventing and responding to future infectious disease crises.
- A Japanese study explored the potential of SGLT2 inhibitors, particularly canagliflozin, in protecting kidney health in patients with type 2 diabetes. - The study used BOLD MRI to monitor kidney oxygenation and found that canagliflozin improved oxygen levels in the kidneys after just five days of use. - Researchers suggest that SGLT2 inhibitors may protect the kidneys by improving oxygenation, potentially offering a therapeutic avenue for diabetic kidney disease. - With the increasing prevalence of diabetes and diabetic nephropathy, canagliflozin represents a potential strategy to mitigate kidney damage.
- Researchers found that Ziziphus jujuba Miller var. spinosa, a traditional Chinese medicine, restored cognitive and motor functions in dementia model mice. - Administering hot water extracts of Zizyphi spinosi semen improved cognitive and motor functions in mice with Alzheimer's, frontotemporal dementia, Parkinson's, and Lewy body dementia. - Crushed Zizyphi spinosi semen powder improved cognitive function in model mice, even surpassing the cognitive levels of control mice. - The herbal medicine also suppressed cellular aging in older mice, improving their cognitive function to levels comparable to younger mice.
- A study of over 500,000 lung cancer patients reveals that BMI affects mortality risk differently in immunotherapy versus chemotherapy. - For NSCLC patients with a BMI under 28, immunotherapy was associated with lower mortality compared to chemotherapy. - In patients with a BMI of 28 or higher, chemotherapy showed a continued decrease in mortality risk, while immunotherapy's risk increased. - Findings suggest BMI should be considered when selecting treatment for advanced non-small cell lung cancer.
